US4361549A
(en)
|
1979-04-26 |
1982-11-30 |
Ortho Pharmaceutical Corporation |
Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
ATE218143T1
(de)
|
1996-09-03 |
2002-06-15 |
Gsf Forschungszentrum Umwelt |
Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
|
PL199659B1
(pl)
|
1998-02-25 |
2008-10-31 |
Merck Patent Gmbh |
Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
EP1071752B1
(en)
|
1998-04-21 |
2003-07-09 |
Micromet AG |
CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
IL141349A0
(en)
|
1998-08-11 |
2002-03-10 |
Idec Pharma Corp |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000042072A2
(en)
|
1999-01-15 |
2000-07-20 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
IL146005A0
(en)
|
1999-05-07 |
2002-07-25 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
EP1395605B8
(en)
|
2001-03-09 |
2014-12-17 |
Iterative Therapeutics, Inc. |
Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
|
WO2003026490A2
(en)
|
2001-09-28 |
2003-04-03 |
Elusys Therapeutics, Inc. |
Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
AU2003208415B2
(en)
|
2002-02-14 |
2009-05-28 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
EP1400534B1
(en)
|
2002-09-10 |
2015-10-28 |
Affimed GmbH |
Human CD3-specific antibody with immunosuppressive properties
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
NZ568769A
(en)
|
2002-10-17 |
2010-04-30 |
Genmab As |
Human monoclonal antibodies against CD20
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
CA2897608C
(en)
|
2003-05-09 |
2018-07-31 |
Duke University |
Cd20-specific antibodies and methods employing same
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
AU2004257142A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
NZ543202A
(en)
|
2003-05-31 |
2008-04-30 |
Micromet Ag |
Pharmaceutical composition comprising a bispecific antibody for epcam
|
EP1629011B1
(en)
|
2003-05-31 |
2010-01-13 |
Micromet AG |
Human anti-human cd3 binding molecules
|
WO2005000899A2
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
JP2007504138A
(ja)
|
2003-08-29 |
2007-03-01 |
ジェネンテック・インコーポレーテッド |
眼疾患の治療法
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
SI1673398T1
(sl)
|
2003-10-16 |
2011-05-31 |
Micromet Ag |
Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
|
MXPA06006865A
(es)
|
2003-12-19 |
2006-08-23 |
Genentech Inc |
Deteccion de cd20 en rechazo de transplante.
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
CA2561533C
(en)
|
2004-04-13 |
2015-06-16 |
Yvo Graus |
Anti-p-selectin antibodies
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
BRPI0510224A
(pt)
|
2004-05-05 |
2007-10-23 |
Genentech Inc |
métodos de prevenção de doença autoimunológica e artigo industrializado
|
EP1753783B1
(en)
|
2004-06-03 |
2014-08-06 |
Novimmune SA |
Anti-cd3 antibodies and methods of use thereof
|
PA8635501A1
(es)
|
2004-06-04 |
2006-06-02 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del lupus
|
CA2580271A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
US20120189643A1
(en)
|
2004-11-30 |
2012-07-26 |
Carton Jill M |
Toll Like Receptor 3 Antagonists, Methods and Uses
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
CN101203242A
(zh)
|
2005-04-22 |
2008-06-18 |
健泰科生物技术公司 |
用cd20抗体治疗痴呆或阿耳茨海默氏病的方法
|
ZA200710496B
(en)
|
2005-06-02 |
2009-04-29 |
Astrazeneca Ab |
Antibodies directed to CD20 and used thereof
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
ES2616316T3
(es)
|
2005-10-11 |
2017-06-12 |
Amgen Research (Munich) Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
|
KR20080073293A
(ko)
|
2005-10-14 |
2008-08-08 |
메디뮨 엘엘씨 |
항체 라이브러리의 세포 디스플레이
|
DK2463305T3
(da)
|
2006-01-12 |
2016-08-29 |
Alexion Pharma Inc |
Antistoffer mod OX-2/CD200 og anvendelser deraf
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
CA3022097C
(en)
|
2006-03-15 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
AU2007227963A1
(en)
|
2006-03-23 |
2007-09-27 |
Kyowa Hakko Kirin Co., Ltd. |
Agonist antibody to human thrombopoietin receptor
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
NZ614857A
(en)
|
2007-03-29 |
2015-04-24 |
Genmab As |
Bispecific antibodies and methods for production thereof
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
FI2155783T4
(fi)
|
2007-04-03 |
2022-12-15 |
|
Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
CN103641919B
(zh)
|
2007-05-30 |
2017-04-05 |
浦项工科大学校产学协力团 |
免疫球蛋白融合蛋白
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008145137A2
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
PL2178916T3
(pl)
|
2007-07-31 |
2015-08-31 |
Regeneron Pharma |
Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
|
CA2695997C
(en)
|
2007-08-10 |
2016-11-22 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
MX342551B
(es)
|
2007-09-26 |
2016-10-04 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
BRPI0817250A2
(pt)
|
2007-09-26 |
2014-06-17 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-receptor da il-6.
|
CN101970494B
(zh)
|
2008-02-20 |
2015-01-21 |
G2炎症私人有限公司 |
人源化抗-C5aR抗体
|
EP2356154A4
(en)
|
2008-11-06 |
2012-12-19 |
Alexion Pharma Inc |
DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
|
JP5798036B2
(ja)
|
2008-11-07 |
2015-10-21 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
小児急性リンパ芽球性白血病の新規治療
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
WO2010063785A2
(en)
|
2008-12-03 |
2010-06-10 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
EP2389192A4
(en)
|
2009-01-23 |
2013-01-16 |
Biogen Idec Inc |
STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
|
JP5787446B2
(ja)
|
2009-03-19 |
2015-09-30 |
中外製薬株式会社 |
抗体定常領域改変体
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
CA2782218C
(en)
|
2009-11-30 |
2018-07-31 |
Janssen Biotech, Inc. |
Antibody fc mutants with ablated effector functions
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
CN105693861A
(zh)
|
2009-12-29 |
2016-06-22 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
WO2011097603A1
(en)
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
CA2794745A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
AU2011244282A1
(en)
*
|
2010-04-20 |
2012-11-15 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
BR112012027917A2
(pt)
|
2010-04-30 |
2017-11-28 |
Alexion Pharma Inc |
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
PL2616489T3
(pl)
|
2010-09-16 |
2017-07-31 |
Baliopharm Ag |
Przeciwciało anty-huTNFR1
|
CN103429737B
(zh)
|
2010-11-30 |
2020-07-14 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
CA2822366A1
(en)
|
2010-12-23 |
2012-06-28 |
Janssen Biotech, Inc. |
Active protease-resistant antibody fc mutants
|
CN103443285B9
(zh)
|
2011-02-08 |
2018-04-24 |
米迪缪尼有限公司 |
特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
|
MX354359B
(es)
|
2011-03-29 |
2018-02-28 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
EP2807194A4
(en)
|
2012-01-27 |
2015-12-02 |
Gliknik Inc |
FUSION PROTEINS WITH IGG2 HINGEOMS
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
RU2014153674A
(ru)
|
2012-06-05 |
2016-07-27 |
Регенерон Фармасьютикалз, Инк. |
Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
|
US20140154253A1
(en)
|
2012-07-13 |
2014-06-05 |
Zymeworks Inc. |
Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
BR122023002590B1
(pt)
|
2013-07-05 |
2023-12-05 |
Genmab A/S |
Anticorpo humanizado ou quimérico de ligação ao cd3 humano, anticorpo biespecífico, microrganismo, composição, composição farmacêutica, uso dos mesmos, método para produzir um anticorpo, composição de diagnóstico, método in vitro para detectar a presença de antígeno cd3, ou uma célula expressando cd3, em uma amostra, kit para detectar a presença de antígeno cd3, ou uma célula que expressa cd3, em uma amostra e anticorpo anti-idiotípico
|
BR112016000666A2
(pt)
|
2013-07-12 |
2017-10-03 |
Zymeworks Inc |
Constructos de ligação de antígeno cd3 e cd19 biespecíficos
|
PE20210107A1
(es)
*
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
RU2016129517A
(ru)
|
2013-12-20 |
2018-01-25 |
Ф. Хоффманн-Ля Рош Аг |
Биспецифические антитела к her2 и способы применения
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI754319B
(zh)
*
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
AU2015350075B2
(en)
|
2014-11-17 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using CD3xCD20 bispecific antibody
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
CA2999385A1
(en)
|
2015-09-23 |
2017-03-30 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-cd3 bispecific antibodies and uses thereof
|
WO2017112762A1
(en)
|
2015-12-22 |
2017-06-29 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia
|